Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting
May 17, 2018 18:15 ET
|
Voyager Therapeutics, Inc.
VY-SOD101 achieves meaningful suppression of disease-causing gene of ALS in large mammals after a one-time administration Results during the second half of 2018 from further delivery optimization...
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
May 17, 2018 09:20 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Presentations
May 08, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2018 Annual Meeting
April 30, 2018 12:15 ET
|
Voyager Therapeutics, Inc.
Five oral presentations and 10 poster presentations focus on Voyager’s clinical and preclinical programs, novel capsid optimization efforts and manufacturing capabilities Investor and analyst...
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
April 30, 2018 12:00 ET
|
uniQure Inc.
New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 30, 2018 (GLOBE NEWSWIRE) --...
Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
May 12, 2017 08:05 ET
|
Abeona Therapeutics Inc
--Positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate GAG observed in Cohort 2--Reduction of disease manifestation observed in decreased...
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
May 08, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
April 24, 2017 14:17 ET
|
Editas Medicine
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell...
Editas Medicine Announces Presentations at Upcoming Scientific Conferences
April 27, 2016 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Editas scientists will present data from its...